Trials / Completed
CompletedNCT01414283
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Progenics Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PSMA ADC | PSMA ADC administered IV |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2013-04-01
- Completion
- 2013-09-01
- First posted
- 2011-08-11
- Last updated
- 2013-11-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01414283. Inclusion in this directory is not an endorsement.